Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
Author:
Affiliation:
1. Department of Haematology Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore, Singapore
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Oncology
Link
https://www.tandfonline.com/doi/pdf/10.1080/14737140.2020.1744438
Reference48 articles.
1. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2. Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer
3. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
4. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Lorlatinib experience in a patient with ALK + non-small cell lung cancer on hemodialysis: A case report;Journal of Oncology Pharmacy Practice;2024-08-14
2. IC Regimen: Delaying Resistance to Lorlatinib in ALK Driven Cancers by Adding Repurposed Itraconazole and Cilostazol;Cells;2024-07-10
3. Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events;Future Oncology;2023-09
4. Recent Advances in the Management of Adverse Events Associated with Lorlatinib;OncoTargets and Therapy;2023-09
5. Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells;International Journal of Molecular Sciences;2022-09-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3